Immortal Dragons, a Singapore-based longevity investment fund, said it has made a strategic investment in Unlimited Bio, a biotechnology company developing combinatorial therapies that target multiple biological systems involved in aging. The fund is described as a US $40 million vehicle focused on radical life-extension technologies.
According to the fund, Unlimited Bio’s platform combines gene therapies, biologics, plasma-based interventions, cell therapies and small-molecule programs aimed at addressing aging as a multi-system failure rather than a single pathway.
Unlimited Bio said that its initial gene therapy portfolio includes targets such as VEGF-A and Follistatin for vascular and muscle health, and a-Klotho and BDNF for cognitive and neuroprotection.
The investment by Immortal Dragons aligns with its previously stated focus on engineering-centric longevity technologies, with Unlimited Bio’s platform positioned to extend the fund’s reach into therapies seeking to enhance healthy lifespan.
Unlimited Bio said its near-term priority is a first-in-human study combining two gene therapies in healthy volunteers, targeted for late 2025 to early 2026 subject to regulatory and ethics approval.
